BridgeBio Pharma (BBIO) Revenue (2019 - 2026)

BridgeBio Pharma's Revenue history runs 8 years deep, the most recent figure standing at $194.5 million for Q1 2026.

• In Q1 2026, Revenue rose 66.78% year-over-year to $194.5 million; the TTM figure through Mar 2026 stood at $580.0 million (up 355.17% YoY), while the FY2025 annual figure was $502.1 million, up 126.26% from the prior year.
• Revenue came in at $194.5 million for Q1 2026 at BridgeBio Pharma, up from $154.2 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $211.1 million in Q1 2024 to a low of $338000.0 in Q3 2022.
• A 5-year average of $59.1 million and a median of $4.1 million in 2023 frame the typical range for Revenue.
• Across the five-year window, Revenue tumbled 97.77% in 2023 and soared 11461.88% in 2024, its largest moves.
• BridgeBio Pharma's Revenue stood at $1.9 million in 2022, then fell by 6.68% to $1.7 million in 2023, then surged by 237.08% to $5.9 million in 2024, then surged by 2521.18% to $154.2 million in 2025, then increased by 26.16% to $194.5 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $194.5 million, $154.2 million, and $120.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison